Sujal M. Patel - 04 Mar 2026 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role: CEO, President, and Secretary, Director, 10%+ Owner
Signature: /s/ Matthew Murphy, as Attorney-in-Fact
Issuer symbol: NAUT
Transactions as of: 04 Mar 2026
Net transactions value: +$65,238
Form type: 4
Filing time: 04 Mar 2026, 18:37:20 UTC
Previous filing: 04 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Patel Sujal M	CEO, President, and Secretary, Director, 10%+ Owner	C/O NAUTILUS BIOTECHNOLOGY, INC., 2701 EASTLAKE AVENUE EAST, SEATTLE	/s/ Matthew Murphy, as Attorney-in-Fact	04 Mar 2026	0001378830

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NAUT	Common Stock	Purchase	$65,238	+25,000	+0.24%	$2.61	10,366,721	04 Mar 2026	Direct	F1
holding	NAUT	Common Stock						5,280,476	04 Mar 2026	By PFV I, LLC	F2
holding	NAUT	Common Stock						1,814,035	04 Mar 2026	By Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2	Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC.
F3	Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.